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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To determine the benefits and harms of marine oil supplements for people with rheumatoid arthritis (RA).
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B A C K G R O U N D
Description of the condition
Rheumatoid arthritis (RA) is a chronic, inflammatory joint disease
that affects up to 1% of the population (Alarcon 1995). The
condition involves predominantly synovial joints and without
appropriate treatment can lead to pain, joint destruction and
permanent disability (Smolen 2016). Ongoing disease activity
can result in extra-articular manifestations, such as vasculitis,
interstitial lung disease and end organ dysfunction (Hurd 1979).
Patients with RA report pain management as their highest priority
(Heiberg 2002). Modern treatment strategies, which emphasise
early and aggressive use of disease-modifying anti-rheumatic
drugs (DMARDs) including biologic DMARDs (bDMARDs), oLen
in combination, have been effective in reducing the burden
of inflammation and subsequent joint damage (Singh 2012;
Smolen 2017). Despite improvements in RA management, the
use of analgesic drugs and non-steroidal anti-inflammatory drugs
(NSAIDs) remains highly prevalent among RA patients (Grijalva
2008; Khanna 2007). Complementary and alternative medicines
(CAMs), including dietary manipulations, are also used commonly
by RA patients. Dietary treatments are the most commonly used
CAM, and of these, marine oil supplements remain the most
prevalent (Buchbinder 2002). The lifetime prevalence of CAM usage
among arthritis sufferers in England is 38% (Ernst 2011), and
estimates of CAM usage by RA patients in the USA range from 28%
to 90% (ELhimiou 2010). Similar findings have been found in other
countries, with 74% of RA patients in an Australian community-
based private practice reporting use of at least one CAM in the
previous year (Buchbinder 2002).
Description of the intervention
Essential fatty acids are required for biological processes and must
be ingested because they are not synthesised in the body. They
comprise the omega-6 (n-6) and omega-3 (n-3) polyunsaturated
fatty acids (PUFAs). Modern Western diets tend to be rich in
n-6 and relatively lacking in n-3 PUFAs (Cleland 2006a). Dietary
supplementation with marine oils provides an abundant source
of the n-3 PUFAs eicosapentaenoic acid (EPA - C20:5n-3) and
docosahexaenoic acid (DHA - C22:6n-3) (Calder 2012; Cleland
2006a). Marine oil supplementation can take the form of capsules
or liquid. They are available in varying doses and types.
How the intervention might work
An anti-inflammatory effect may be derived from an increase
in the ratio of n-3 to n-6 PUFAs in cell membranes (Calder
2012). Normally, the n-6 PUFA, (AA - C20:4n-6) is metabolised
by cyclooxygenase (COX) enzymes to inflammatory eicosanoids
including prostaglandin E2 and leukotriene B4. In contrast, the
n-3 PUFAs, EPA and DHA, are metabolised by COX to less
inflammatory eicosanoids. Both omega-6 and omega-3 PUFAs are
substrates for COX. Thus, an increase in the relative proportion
of n-3 PUFAs in cell membranes has the potential to reduce the
production of pro-inflammatory molecules. More COX activity is
directed towards the n-3 pathway, theoretically producing less
inflammatory eicosanoids. Furthermore, EPA and DHA may be
metabolised to resolvins, a family of bioactive molecules with
potent anti-inflammatory activity (Seki 2010). Amelioration of
inflammation via these or other mechanisms in individuals with
RA may reduce symptoms or allow a reduction in the use of
NSAIDs, which carry a risk of adverse gastrointestinal, renal and
cardiovascular effects (McGettigan 2011; Ng 2010). A daily dose of
at least 2.7 grams of n-3 PUFAs is thought to be required to achieve
an anti-inflammatory effect, and any symptomatic benefit may be
delayed for up to three months (Cleland 2006a; Cleland 2006b).
On mechanistic grounds, the effect of dietary supplementation
with n-3 PUFAs on RA activity is likely to resemble that of
NSAIDs - namely reduction in pain and stiffness. Nevertheless,
one observational study demonstrated a significantly higher rate
of disease remission in RA patients who took regular fish oil
supplements in addition to DMARDs, compared with those using
DMARDs alone, which suggests a potential disease-modifying effect
of marine oils (Cleland 2006a).
A further putative benefit of marine oils is a reduction in
cardiovascular risk. Patients with RA are known to be at increased
risk for cardiovascular events (Peters 2009). Contributors to this
increase in risk include both traditional risk factors and RA disease
activity itself, in addition to RA medications, particularly NSAIDS
(McGettigan 2011; Solomon 2010). Marine oils are thought to
reduce cardiovascular risk via multiple mechanisms, including anti-
thrombotic, anti-arrhythmic and anti-inflammatory effects and
an improvement in lipid profile (Hooper 2004). Such benefits
may be of particular relevance to individuals with RA. Should
marine oil supplements allow a reduction in NSAID use, this may
further attenuate the elevated cardiovascular risk faced by RA
patients. While fish oil has been shown to improve lipid profiles in
people with RA (Cleland 2006a), there is moderate to high-quality
evidence that omega-3 supplementation has little or no effect on
cardiovascular health in the general population (Abdelhamid 2018).
Why it is important to do this review
While some evidence exists for an analgesic and NSAID-sparing
effect of marine oil supplementation in RA (James 2010), and a
favourable effect on cardiovascular risk factors (Cleland 2006a),
doubt remains about the efficacy and safety of marine oils as
an adjunct to existing therapies in this population. Two previous
studies suggested a beneficial effect of fish oil supplementation on
pain, tenderness and morning stiffness in RA (Fortin 1995; Goldberg
2007). However, neither study comprehensively assessed both pain
and disease activity outcomes, nor were potential harmful effects
addressed. Both studies performed meta-analyses but restricted
their literature search to English language papers, and Goldberg
2007 included patients with other painful conditions in addition to
RA. A more recent systematic review suggested a small favourable
effect of marine oil supplements in reducing pain in patients with
arthritis and potential benefit in those with RA (SenLleber 2017).
Despite the existing literature, current consensus guidelines for
management of RA do not discuss the role of marine oils (Singh
2016; Smolen 2017), and neither do multinational evidence-based
recommendations for pain management by pharmacotherapy in
inflammatory arthritis (Whittle 2012). However, the use of marine
oil supplements appears to be prevalent among RA patients in
some parts of the world. In a community-based cohort in South
Australia, fish oil use was reported by 6% of the general community
and 18.8% of those with self-reported RA (Hill 2009). Potential
harms of marine oil supplementation, particularly at high doses,
include prolonged bleeding time, gastrointestinal intolerance,
contamination with mercury and other environmental toxins,
and interaction with prescription medications (Cleland 2006b;
Melanson 2005; Salisbury 2012; Stanger 2012). The prevalence
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and clinical importance of such effects at commonly used doses
remains unclear. Clarification of the efficacy and safety of marine
oil supplementation in this population is therefore required.
O B J E C T I V E S
To determine the benefits and harms of marine oil supplements for
people with rheumatoid arthritis (RA).
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include all published randomised controlled trials (RCTs).
We will not impose any restrictions on length of follow-up or
language of the paper. We will only include trials that are published
as full articles or are available as a full trial report.
Types of participants
Adults (aged 18 years or older) with a diagnosis of rheumatoid
arthritis (RA). We will exclude studies that include a mixed
population of people with RA and other types of arthritis, unless we
can separate out the results for the RA population in the analysis.
Types of interventions
We will include all studies that evaluate marine oil supplements. We
will not impose any restrictions on the formulation of marine oil.
We will include studies that evaluate marine oils as a supplement
to other therapies, or, if available, studies that evaluate marine oil
supplements as sole therapy for RA. We will include all possible
variations (type, dosage, intensity, mode of delivery, frequency
of delivery, duration of delivery, timing of delivery). We will also
include trials with co-intervention in one group only (e.g. marine




2. different types, doses or formulations of marine oil;
3. analgesic medications, such as paracetamol or non-steroidal
anti-inflammatory drugs (NSAIDs);
4. DMARDs (including conventional synthetic DMARDs (csDMARDs)
and biologic DMARDs (bDMARDs));
5. non-pharmacological modalities (e.g. acupuncture, massage,
transcutaneous electrical nerve stimulation (TENS)); and
6. any of the above in combination.
Types of outcome measures
Although marine oil supplementation in RA might have a disease-
modifying effect, it is primarily used in clinical practice for its anti-
inflammatory effect. Therefore, we consider that the most relevant
patient outcomes are pain, function, quality of life, withdrawals due
to adverse events, serious and total adverse events. Therefore these
will be the six major outcomes in this review.
Major outcomes
1. Pain: measured as proportion of participants with a clinically
important reduction in pain or mean pain, measured on a visual
analogue scale, numerical rating scale or other scale.
2. Function: measured by the Health Assessment Questionnaire
(HAQ; Fries 1980; Pincus 1983), Arthritis Impact Measurement
Scale (AIMS; Meenan 1980), or other scales reported by authors.
3. Health-related quality of life: measured by the Medical
Outcomes Study Short-Form Health Survey (SF-36) mental
component and physical component, or any other scales
reported by authors (Ware 1994).
4. Withdrawals due to adverse events.
5. Morning stiffness: measured as duration of morning stiffness.
6. Total adverse events: number of participants reporting an
adverse event and type of adverse event.
Minor outcomes
1. Criteria for improvement: American College of Rheumatology
(ACR) response criteria for 50% improvement (Felson 2011) ACR
50, which is defined as an improvement in response rates of 50%
in tender and swollen joints, in addition to a 50% improvement
observed in three out of five core measures, such as patient
and physical global assessments, pain, functional status and an
acute phase reactant.
2. Disease activity: measured by the Disease Activity Score in 28
joints (DAS28) or 44 joints (DAS44). In addition, we will consider
remission rates as a useful measure of the disease activity
measured in the range of either a DAS < 1.6 or < 2.6 (Prevoo
1995), or ACR/European League Against Rheumatitis (EULAR)
2011 remission definition, either Boolean (total joint count (TJC)
1, swollen joint count (SJC) 1, C-reactive protein (CRP) 1 mg/dL,
patient global assessment 1) or index-based (Simplified Disease
Activity Index ≤ 3.3) (Felson 2011).
3. ACR 20 and 70, which is defined as an improvement in response
rates of 20% and 70% in tender and swollen joints, in addition
to a 20% or 70% improvement observed in three out of five
core measures, such as patient and physical global assessments,
pain, functional status and an acute phase reactant.
4. Individual core measures: number of tender joints per patient;
number of swollen joints per patient; pain (visual analogue
scale (VAS)); physician global assessment (VAS); patient global
assessment (VAS); acute phase reactants - including erythrocyte
sedimentation rate (ESR; a measurement of how fast red blood
cells (erthrocytes) fall to the bottom of a test tube filled with
whole blood; those with RA have high levels of sedimentation).
5. Radiographic progression: measured by radiographic scores to
detect a change in the score from baseline, which include:
i) modified total Sharp score, with score range 0 to 448
(van der Heijde 1999); ii) erosion score; and iii) joint space
narrowing score. Scores for erosions and joint space narrowing
are summed to yield the total Sharp score.
6. Analgesic consumption (including NSAIDs, paracetamol and
opioids).
7. Serious adverse events.
8. Cardiovascular events (deaths or acute coronary syndromes).
We will evaluate the outcomes for the following endpoints, if
available in the included studies: (a) short term (< 12 weeks), and
(b) long term (≥ 12 weeks).
Marine oil supplements for rheumatoid arthritis (Protocol)
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Search methods for identification of studies
Electronic searches
We will use the highly sensitive Cochrane search strategy, which
aims to identify all RCTs (Lefebvre 2011), and specific MeSH
headings and additional keywords to identify all RCTs on marine
oils in RA. We will search the following databases for RCTs or
controlled clinical trials (CCTs) using search strategies developed in
conjunction with an experienced librarian.
1. Cochrane Central Register of Controlled Trials (CENTRAL)
(Appendix 1)
2. OVID MEDLINE 1946 to present (Appendix 2)
3. EMBASE 1980 to present (Appendix 2)
4. Clinicaltrials.gov (clinicaltrials.gov)
5. World Health Organization International Clinical Trials Registry
(apps.who.int/trialsearch)
We will not apply any language restrictions.
Searching other resources
We will inspect the reference lists of included studies and other
systematic reviews on marine oil supplementation in RA for
additional trials.
We will also search abstracts from the two major international
rheumatology scientific meetings in 2018 and 2019 (American
College of Rheumatology (ACR) and the European League Against
Rheumatism (EULAR)) to identify unpublished studies.
Data collection and analysis
Selection of studies
Pairs of reviewers will independently assess each title and
abstract for suitability for inclusion in the review according
to predetermined selection criteria (see Criteria for considering
studies for this review). If there is any doubt, the full text article
will be retrieved and read by the reviewers. Disagreements between
the reviewers about the eligibility of the articles will be discussed
in a consensus meeting. In case of non-consensus between the
reviewers, a third reviewer will decide if the study is eligible.
Data extraction and management
Pairs of reviewers will independently extract the data regarding
study design, study duration, characteristics of study population,
interventions (including comparators), outcome measures and
timing of outcome assessment, co-interventions, efficacy and
adverse effect data, and loss to follow-up using a standardised data
extraction form. Differences in data extraction will be resolved by
referring back to the original articles and establishing consensus.
A third reviewer will be consulted to help resolve differences, if
necessary.
We will extract the results (i.e. raw data: means and standard
deviations (SDs) for continuous outcomes and number of events
for dichotomous outcomes) for outcomes of interest in order to
assess efficacy and safety. For studies published in languages other
than English, German, Portuguese, French, Spanish or Dutch, we
will obtain the help of a native speaker or translator with content
and methodological expertise.
Assessment of risk of bias in included studies
Pairs of reviewers will independently assess the risk of bias
of each included study with regard to the following items:
random sequence generation, allocation concealment, blinding
of participants, care provider, and outcome assessor for each
outcome measure (see Types of outcome measures), incomplete
outcome data, selective outcome reporting, and other sources of
bias, conforming to the methods recommended in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2017).
To determine the risk of bias of a study, for each criterion we will
evaluate the presence of sufficient information and the likelihood
of potential bias. We will rate each criterion as 'yes' (low risk of
bias), 'no' (high risk of bias) or 'unclear' (either lack of information
or uncertainty over the potential for bias). We will hold a consensus
meeting to discuss and resolve disagreements. If consensus cannot
be reached, a third reviewer (RB) will make the final decision.
Measures of treatment effect
We will analyse dichotomous data as risk ratios (RRs) and use 95%
confidence intervals (CIs). We will enter data presented as a scale
with a consistent direction of effect across studies.
For continuous data, we will analyse results as mean differences
(MDs) between the intervention and comparator group, with
corresponding 95% CIs. However, when different scales are used
to measure the same conceptual outcome (e.g. functional status
or pain), we will calculate standardised mean differences (SMDs)
instead, with corresponding 95% CIs. Upon completion of the
analysis, we will back-translate the SMD to a typical scale (e.g. 0
to 10 for pain) by multiplying the SMD by a typical among-person
SD (e.g. the SD of the control group at baseline from the most
representative trial) (Schünemann 2017b). We will calculate the
absolute benefit as the improvement in the intervention group
minus the improvement in the control group, in the original units,
expressed as a percentage. We will calculate the relative difference
in the change from baseline as the absolute benefit divided by the
baseline mean of the control group, expressed as a percentage.
In the 'Effects of interventions' results section and the 'Comments'
column of the 'Summary of findings' table, we will provide the
absolute percentage difference, the relative percentage change
from baseline, and the number needed to treat for an additional
beneficial outcome (NNTB), or the number needed to treat for an
additional harmful outcome (NNTH) (we will only provide the NNTB
or NNTH when the outcome shows a clinically important difference
between groups). For pain, we will assume a minimal clinically
important difference (MCID) of 1.5 on a 0 to 10-point scale (Farrar
2001), and for the Health Assessment Questionnaire (HAQ) we will
assume a MCID of 0.22 (Kosinski 2000; Wells 1993).
For dichotomous outcomes, we will calculate the NNTB or NNTH
from the control group event rate and the relative risk using
the Visual Rx NNT calculator (Cates 2008). We will calculate the
NNTB or NNTH for continuous measures using the Wells calculator
(available at the Cochrane Musculoskeletal editorial office). We will
calculate the absolute risk difference (RD) using GRADEpro soLware
(GRADEpro GDT 2015), and express the result as a percentage. We
will calculate the relative percentage change for dichotomous data
as the RR - 1 and express this as a percentage.
Marine oil supplements for rheumatoid arthritis (Protocol)
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Unit of analysis issues
We do not expect major unit of analysis problems in this review. In
the event that we identify cross-over trials, in which the reporting
of continuous outcome data precludes paired analysis, we will not
include these data in a meta-analysis, in order to avoid unit of
analysis error.  Where carry-over effects are thought to exist, and
where sufficient data exist, we will only include data from the first
period in the analysis (Higgins 2011a).
For studies containing more than two intervention groups, making
multiple pair-wise comparisons between all possible pairs of
intervention groups possible, we will include the same group of
participants only once in the meta-analysis. If more than one
intervention group can be included in our subgroup analyses, we
will extract the data from both arms with that goal.
In the case of a trial with multiple time points in which the outcomes
are assessed, we will choose the time point closest to our cut-off
(12 weeks).
Dealing with missing data
Where important data are missing or incomplete, we plan to seek
further information from the study authors.
In cases where individuals are missing from the reported results,
we will assume the missing values to have a poor outcome. For
dichotomous outcomes (e.g. number of withdrawals due to adverse
events), we will calculate the withdrawal rate using the number of
patients randomised in the group as the denominator (worst-case
analysis).
For continuous outcomes (e.g. mean change in pain score), we
will calculate the MD or SMD based on the number of patients
analysed at that time point. If the number of patients analysed
is not presented for each time point, we will use the number of
randomised patients in each group at baseline.
Where possible, we will compute missing SDs from other statistics,
such as standard errors, CIs or P values, according to the methods
recommended in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011b). If we cannot calculate SDs, we will
impute them (e.g. from other studies in the meta-analysis) (Higgins
2011a).
Assessment of heterogeneity
In this review, we will explore both clinical and statistical
heterogeneity between the studies.
Firstly, we will assess studies for clinical homogeneity with
respect to the study population, intervention groups (marine
oil formulations, dosages), control groups, timing of outcome
assessment and outcome measures.
For any studies judged as clinically homogeneous, we will assess
statistical heterogeneity with the I2 statistic (Deeks 2017), using the
following as a rough guide for interpretation: 0% to 40% might not
be important; 30% to 60% may represent moderate heterogeneity;
50% to 90% may represent substantial heterogeneity; and 75%
to 100% considerable heterogeneity. In cases of considerable
heterogeneity (defined as I2 ≥ 75%), we will explore the data
further, including subgroup analyses, in an attempt to explain the
heterogeneity (Deeks 2017).
Assessment of reporting biases
In order to determine whether reporting bias is present, we will
determine whether the protocol of the RCT was published before
recruitment of patients of the study was started. For studies
published aLer 1 July 2005, we will screen the Clinical Trial Register
at the International Clinical Trials Registry Platform of the World
Health Organization (apps.who.int/trialsearch; DeAngelis 2004). We
will evaluate whether selective reporting of outcomes is present
(outcome reporting bias).
We will compare the fixed-effect estimate against the random-
effects model to assess the possible presence of small sample bias
in the published literature (i.e. in which the intervention effect
is more beneficial in smaller studies). In the presence of small
sample bias, the random-effects estimate of the intervention is
more beneficial than the fixed-effect estimate (Sterne 2017).
We will further explore the potential for reporting bias using funnel
plots if at least 10 studies or more are available.
Data synthesis
We will pool the results of clinically and statistically homogeneous
studies using the random-effects model, per default, and using a
fixed-effect model in sensitivity analyses. When assessing clinical
homogeneity, we will take into account the types of interventions,
comparators and the study population. If it is possible for us to
meta-analyse, then we will conduct pooling in such a way that
we will take into account the different comparators and analyse
them separately. We will perform analyses using Review Manager
5 (Review Manager 2014), and produce forest plots for all analyses.
We will present the results for all the studies first and then split
them into subgroups, where data are available, to explore potential
sources of heterogeneity.
'Summary of findings' table
We will present the main results of the review in a 'Summary of
findings' table, which will include an overall grading of the evidence
using the GRADE approach (GRADEpro) and a summary of the
available data on the main outcomes as described in chapter 11
of the Cochrane Handbook for Systematic Reviews of Interventions
(Schünemann 2017a). We will present marine oil supplements
versus placebo in the 'Summary of findings' table. We will include
an additional table to summarise the minor outcomes.




3. Health-related quality of life
4. Withdrawals due to adverse events
5. Morning stiffness
6. Total adverse events
Grading of the evidence involves consideration of within-study risk
of bias, directness of evidence, heterogeneity, precision of effect
estimates and risk of publication bias. However, other factors can
affect the quality of evidence, for example, it can be increased
by a large magnitude of effect, plausible confounding, and dose-
response gradients. Using this system, we will grade the quality of
Marine oil supplements for rheumatoid arthritis (Protocol)
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the body of evidence as high, moderate, low or very low (GRADE
Working Group 2004).
Subgroup analysis and investigation of heterogeneity
Where sufficient data are available, we plan to perform the
following subgroup analyses.
1. High-dose (≥ 2.7 g/day) versus low-dose n-3 polyunsaturated
fatty acid (PUFA) supplementation - it has been suggested that
a daily dose of n-3 PUFA or at least 2.7 grams is required
to achieve an anti-inflammatory effect, although the putative
cardiovascular benefits may occur at lower doses (Cleland
2006a; Cleland 2006b).
2. Marine oil supplementation for < three months versus ≥ three
months - it is thought that it may take up to three months for
the full symptomatic benefit of n-3 PUFA supplementation to be
achieved (Cleland 2006a; Cleland 2006b).
3. Liquid marine oil versus marine oil capsules - marine oil
supplements are typically consumed in one of these two
preparations; liquid marine oil is thought to provide a more
convenient and cheaper method of consuming a high dose of
n-3 PUFAs, but it is not clear whether the two preparations are
otherwise equivalent (Cleland 2006b).
4. Disease duration < 12 months versus ≥ 12 months - although
there is no clear definition of early arthritis and what it means in
terms of disease duration, most trials in early RA include patients
with < 12 months duration (Bakker 2012; van Vollenhoven 2012).
For analyses 1 to 3, we expect that we will compare outcomes
from different trials, e.g. high-dose marine oil versus placebo in
one trial and low-dose marine oil versus placebo in another trial.
For analysis 4, we expect to extract within-trial data, i.e. trials that
report these subgroups separately.
Where available, we will extract data on subgroups and present
with subgroup totals. We will compare the magnitude of the effects
between the subgroups by means of assessing the overlap of the
CIs of the summary estimated. Non-overlap of the CIs indicates
statistical significance.
Sensitivity analysis
Where sufficient studies exist, we plan to conduct sensitivity
analyses to assess the impact of any bias attributable to inadequate
or unclear treatment allocation (including studies with quasi-
randomised designs), blinding of patient/assessor and loss to
follow-up compared to studies without these study limitations
('yes' versus 'no' or 'unclear').
A C K N O W L E D G E M E N T S
Elements of the methods section are based on the standard
Cochrane Musculoskeletal Group Protocol Template.
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Appendix 1. CENTRAL search strategy
BOX 1
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fatty acids OR essential fatty acids OR EFA OR polyunsaturated OR PUFA OR omega3 OR omega-3 OR EPA OR DHA OR eicosapentaen
OR docosahexaeno OR icosapentaenoic OR ((fish OR krill OR Euphausiacea OR marine OR haddock OR cod OR Gadiformes OR salmon
OR Salmon OR mackerel OR herring OR anchov OR sardine OR tuna OR Tuna OR skipjack OR halibut OR Flounder OR coalfish OR shark
OR Sharks OR whale OR Whales OR Seals, Earless OR Fur Seals OR seal OR calamari OR squid OR Decapodiformes OR (algae or algal)
OR spirulina OR Spirulina OR seaweed or Seaweed OR euphausia superba OR haematococcus pluvialis OR lithothamnion calcareum OR
(lithothamnion adj (calcareum or corallioides)) OR dulse OR ascophyllum nodosum OR Chlorella OR chlorella OR gigartina OR mussel OR
exp Bivalvia OR perna canaliculus) AND (oil OR fatty acid OR triglyceride OR lipid))
BOX 2
arthritis rheumatoid OR (rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat or reumat or revmarthrit)
adj3 (arthrit or artrit or diseas or condition or nodule) OR (felty adj2 syndrome) OR (caplan adj2 syndrome) OR (sjogren adj2 syndrome) OR
(sicca adj2 syndrome) OR still disease AND (disease OR condition OR syndrome OR nodule)
Appendix 2. OVID MEDLINE and EMBASE search strategy
1. exp arthritis rheumatoid/
2. ((rheumatoid or reumatoid or revmatoid or rheumatic or reumatic or revmatic or rheumat$ or reumat$ or revmarthrit$) adj3 (arthrit$
or artrit$ or diseas$ or condition$ or nodule$)).tw.
3. (felty$ adj2 syndrome).tw.
4. (caplan$ adj2 syndrome).tw.
5. (sjogren$ adj2 syndrome).tw.









15. (EPA or DHA).tw.
16. (eicosapentaen$ or icosapentaenoic or docosahexaeno$).tw.
17. fish.tw.
18. krill.tw. or Euphausiacea/
19. marine.tw.
20. haddock.tw.
21. cod.tw. or Gadiformes/





27. tuna.tw. or Tuna/
28. skipjack.tw.
29. halibut.tw. or Flounder/
30. coalfish.tw.
31. shark$.tw. or Sharks/
32. whale$.tw. or Whales/
33. Seals, Earless/ or Fur Seals/ or seal.tw.
34. calamari.tw.
35. squid.tw. or Decapodiformes/
36. (algae or algal).tw.
37. spirulina.tw. or Spirulina/




42. (lithothamnion adj (calcareum or corallioides)).tw.
43. dulse.tw.
44. ascophyllum nodosum.tw.
45. Chlorella/ or chlorella.tw.
46. gigartina.tw.
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47. mussel$.tw. or exp Bivalvia/
48. perna canaliculus.tw.
49. or/9-48
50. randomized controlled trial.pt.








59. exp animals/ not humans.sh.
60. 58 not 59
61. and/8,49,60
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